Ignite Creation Date:
2025-12-24 @ 12:47 PM
Ignite Modification Date:
2025-12-27 @ 9:39 PM
Study NCT ID:
NCT05469061
Status:
UNKNOWN
Last Update Posted:
2022-07-21
First Post:
2022-06-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-08
First Submit QC Date:
None
Study First Post Date:
2022-07-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-19
Last Update Post Date:
2022-07-21
Last Update Post Date Type:
ACTUAL